> For the complete documentation index, see [llms.txt](https://docs.rplpeptides.com/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://docs.rplpeptides.com/docs/tirzepatide/stability-guides/tirzepatide-stability-guide.md).

# tirzepatide-stability-guide

RPL Peptide

Official Technical Documentation

Stability Guide

***

## Stability Guide — Tirzepatide

### Stability Summary

| Form                          | Storage Condition | Stability Period |
| ----------------------------- | :---------------: | :--------------: |
| **Lyophilized**               |       -20°C       |     2+ years     |
| **Lyophilized**               |       2–8°C       |     12 months    |
| **Lyophilized**               |  25°C (Room Temp) |      30 days     |
| **Reconstituted**             |       2–8°C       |      30 days     |
| **Reconstituted**             |        25°C       |      7 days      |
| **Reconstituted (Aliquoted)** |       -20°C       |     6 months     |

### Stability Testing Parameters

Stability is monitored using the following analytical methods:

| Test              | Method            |           Frequency           |
| ----------------- | ----------------- | :---------------------------: |
| **Appearance**    | Visual inspection |        Each time point        |
| **Purity**        | HPLC (214 nm)     |        Each time point        |
| **Identity**      | LC-MS             | Initial and final time points |
| **pH**            | pH meter          |        Each time point        |
| **Water Content** | Karl Fischer      |          Initial only         |
| **Endotoxin**     | LAL               |          Initial only         |

### Accelerated Stability Data

|     Condition     | Duration | Expected Purity Retention |
| :---------------: | :------: | :-----------------------: |
| **40°C / 75% RH** |  2 weeks |            ≥98%           |
| **40°C / 75% RH** |  4 weeks |            ≥97%           |
| **25°C / 60% RH** | 3 months |            ≥98%           |
| **25°C / 60% RH** | 6 months |            ≥97%           |

### Degradation Pathways

| Pathway              |          Risk          | Mitigation                                    |
| -------------------- | :--------------------: | --------------------------------------------- |
| **Hydrolysis**       |         Medium         | Keep dry; low moisture content                |
| **Oxidation**        |       Low-Medium       | Protect from air; inert atmosphere            |
| **Deamidation**      |           Low          | Maintain pH 4.0–6.5                           |
| **Aggregation**      |           Low          | Avoid vigorous shaking; proper reconstitution |
| **Microbial Growth** | Medium (reconstituted) | Use bacteriostatic water; sterile technique   |

### Stability Testing Protocol

#### Real-Time Stability

* **Storage**: -20°C and 2–8°C
* **Time Points**: 0, 1, 3, 6, 12, 18, 24 months
* **Samples**: Triplicate vials per time point
* **Testing**: Appearance, purity (HPLC), identity (LC-MS), pH, moisture

#### Accelerated Stability

* **Storage**: 25°C/60% RH and 40°C/75% RH
* **Time Points**: 0, 2, 4, 8, 12 weeks
* **Samples**: Triplicate vials per time point
* **Testing**: Appearance, purity (HPLC), pH

### Freeze-Thaw Stability

| Freeze-Thaw Cycles | Purity Retention |
| :----------------: | :--------------: |
|     **1 cycle**    |       ≥99%       |
|    **3 cycles**    |       ≥98%       |
|    **5 cycles**    |       ≥97%       |
|    **10 cycles**   |       ≥95%       |

> **Note**: Repeated freeze-thaw cycles are not recommended. Aliquot reconstituted peptide for single-use applications.

### Handling Effects on Stability

| Condition               |   Effect on Stability   | Recommendation                 |
| ----------------------- | :---------------------: | ------------------------------ |
| **Light exposure**      |   Moderate degradation  | Store in dark; use amber vials |
| **Temperature spikes**  | Accelerated degradation | Maintain cold chain            |
| **Vortexing**           |  Potential aggregation  | Swirl gently only              |
| **Dilution in buffers** |     Generally stable    | Use recommended buffers        |
| **Metal ion contact**   |   Potential chelation   | Use low-binding labware        |

### Stability Indicators

| Indicator       | Sign of Degradation                          |
| --------------- | -------------------------------------------- |
| **Visual**      | Discoloration, cloudiness, precipitation     |
| **HPLC**        | Decreased main peak area; new impurity peaks |
| **pH**          | Significant pH shift (>1.0 unit)             |
| **Bioactivity** | Reduced receptor binding (functional assay)  |

***

© 2026 RPL Peptide

Official Technical Documentation

rplpeptides.com


---

# Agent Instructions
This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com.

## Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.

Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter:

```
GET https://docs.rplpeptides.com/docs/tirzepatide/stability-guides/tirzepatide-stability-guide.md?ask=<question>&goal=<endgoal>
```

`ask` is the immediate question: it should be specific, self-contained, and written in natural language.
`goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal.

The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.

Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.